[1]李星 袁振芳.肥胖型2型糖尿病的内科治疗进展[J].中华肥胖与代谢病电子杂志,2016,2(03):133-137.[doi:10.3877//cma.j.issn.2095-9605.2016.03.003]
点击复制

肥胖型2型糖尿病的内科治疗进展()
分享到:

《中华肥胖与代谢病电子杂志》[ISSN:2095-9605/CN:11-9362]

卷:
第2卷
期数:
2016年03期
页码:
133-137
栏目:
专家论坛
出版日期:
2016-09-18

文章信息/Info

作者:
李星 袁振芳
100034 北京大学第一医院内分泌科
关键词:
肥胖症 糖尿病 2型 内科治疗
DOI:
10.3877//cma.j.issn.2095-9605.2016.03.003

参考文献/References:

[1] Sieck G. Physiology in perspective: the burden of obesity[J]. Physiology (Bethesda), 2014, 29(2):86-87.
[2] 林晓斐 . 《中国居民营养与慢性病状况报吿(2015 年)》发布 [J]. 中医药管理杂志 , 2015, 23(13):89.
[3] Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2):137-149.
[4] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9):948-959.
[5] Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease[J]. Diabetes, 1988, 37(12):1595-1607.
[6] Hartstra AV, Bouter KE, B?ckhed F, et al. Insights into the role of the microbiome in obesity and type 2 diabetes[J]. Diabetes care, 2015, 38(1):159-165.
[7] Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future[J]. Lancet, 2014, 383(9922):1068-1083.
[8] American Heart Association, American College of Cardiology, Obesity Society. Reprint: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults[J]. J Am Pharm Assoc (2003), 2014, 54(1):e3.
[9] 陆菊明 . 中国 2 型糖尿病防治指南(2013 年版)更新要点的解读 [J]. 中国糖尿病杂志 , 2014, 22(10):865-869.
[10] Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look ahead trial[J]. Arch Intern Med, 2010, 170(17):1566-1575.
[11] Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study[J]. The Lancet, 2008, 371(9626):1783-1789.
[12] Lindstr?m J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity[J]. Diabetes care, 2003, 26(12):3230-3236.
[13] Lindstr?m J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow- up of the Finnish diabetes prevention study[J]. Lancet, 2006, 368(9548):1673-1679.
[14] Sun F, Chai S, Li L, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis[J]. J Diabetes Res, 2015(2015):157201.
[15] Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial[J]. Lancet Diabetes Endocrinol, 2014, 2(1):46-55.
[16] Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J]. Curr Med Res Opin, 2008, 24(1):275-286.
[17] Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52- week, phase III, double-blind, parallel-treatment trial[J]. Lancet, 2009, 373(9662):473-481.
[18] Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2010, 375(9733):2223-2233.
[19] ]Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
[20] Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss[J]. Ann Pharmacother, 2010, 44(3):538-545.
[21] Gault VA, Bhat VK, Irwin N, et al. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice[J]. J Biol Chem, 2013, 288(49):35581-35591.
[22] Bhat VK, Kerr BD, Vasu S, et al. A DPP-IV-resistant triple- acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice[J]. Diabetologia, 2013, 56(6):1417-1424.
[23] Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients[J]. Diabetes care, 2004, 27(1):155-161.
[24] Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5‐HT(2C) agonist, reduces body weight in obese men and women[J]. Obesity (Silver Spring), 2009, 17(3):494-503.
[25] Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)[J]. Obesity (Silver Spring), 2012, 20(2):330-342.
[26] Allé N. Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo[EB/OL]. [2016-03-30]. http://www.europeanpharmaceuticalreview.com/25844/news/industry- news/phase-3a-liraglutide-3-mg-trial-demonstrated-significant- weight-loss-improved-cardiovascular-risk-factors-adults-obesity-type- 2-diabetes-compared-placebo/.
[27] Astrup A, R?ssner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study[J]. Lancet, 2009, 374(9701):1606-1616.
[28] Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the scale maintenance randomized study[J]. Int J Obes (Lond), 2013, 37(11):1443-1451.

相似文献/References:

[1]褚薛慧 单晓东 邱晨 邓玲 孙喜太.多学科诊疗模式在代谢手术中的应用价值[J].中华肥胖与代谢病电子杂志,2016,2(01):12.[doi:10.3877//cma.j.issn.2095-9605.2016.01.003]
 Chu Xuehui,Shan Xiaodong,Qiu chen,et al.Application value of multidisciplinary treatment mode in metabolic surgery[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2016,2(03):12.[doi:10.3877//cma.j.issn.2095-9605.2016.01.003]
[2]康建省 李涛 马利锋 张立超 刘金鸽.腹腔镜袖状胃切除术在治疗病态肥胖症中的应用价值[J].中华肥胖与代谢病电子杂志,2016,2(01):17.[doi:10.3877//cma.j.issn.2095-9605.2016.01.004]
 Kang Jiansheng,LiTao,Ma Lifeng,et al.Application value of laparoscopic sleeve gastrectomy in treating morbid obesity[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2016,2(03):17.[doi:10.3877//cma.j.issn.2095-9605.2016.01.004]
[3]陈宏 雒洪志 周小雕 余元龙 梁义 王存川.腹腔镜Roux-en-Y 胃旁路术在治疗肥胖型2 型糖尿病中的应用价值[J].中华肥胖与代谢病电子杂志,2016,2(01):26.[doi:10.3877//cma.j.issn.2095-9605.2016.01.006]
 Chen Hong,Luo Hongzhi,Zhou Xiaodiao,et al.Application value of laparoscopic Roux-en-Y gastric bypass in treating obese type 2 diabetes mellitus[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2016,2(03):26.[doi:10.3877//cma.j.issn.2095-9605.2016.01.006]
[4]林玉芳 廖继武 黄俏庭 潘集阳.肥胖症的精神药物和心理治疗研究进展[J].中华肥胖与代谢病电子杂志,2016,2(01):46.[doi:10.3877//cma.j.issn.2095-9605.2016.01.011]
[5]何肖 胡雷 陈栋.肥胖症与男性不育症相关性的研究进展[J].中华肥胖与代谢病电子杂志,2016,2(01):49.[doi:10.3877//cma.j.issn.2095-9605.2016.01.012]
[6]邹启荣 李佳阳 彭雪梅.容量控制通气模式和压力控制通气模式对病态肥胖症患者循环功能的影响[J].中华肥胖与代谢病电子杂志,2015,1(03):122.[doi:10.3877//cma.j.issn.2095-9605.2015.03.003]
 Zou Qirong,Li Jiayang,Peng Xuemei..Effects of volume controlled ventilation and pressure controlled ventilation on morbidly obese patients[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2015,1(03):122.[doi:10.3877//cma.j.issn.2095-9605.2015.03.003]
[7]何辉 李开春 李浩然 金实 董擂 程雷 李克军.腹腔镜Roux-en-Y胃旁路术在治疗2型糖尿病中的应用价值[J].中华肥胖与代谢病电子杂志,2015,1(03):137.[doi:10.3877//cma.j.issn.2095-9605.2015.03.006]
 He Hui,Li Kaichun,Li Haoran,et al.Clinical application value of laparoscopic Roux-en-Y gastric bypass for the treatment of type 2 diabetes mellitus[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2015,1(03):137.[doi:10.3877//cma.j.issn.2095-9605.2015.03.006]
[8]赵象文 关凯林 华伟 韩月峰 马育林 梁国仲.精准腹腔镜Roux-en-Y胃旁路术治疗肥胖型2型糖尿病的临床应用价值[J].中华肥胖与代谢病电子杂志,2015,1(03):142.[doi:10.3877//cma.j.issn.2095-9605.2015.03.007]
 Zhao Xiangwen,Guan Kailin,Hua Wei,et al.Clinical application value of precise laparoscopic Roux-en-Y gastric bypass for obese T2DM Zhao[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2015,1(03):142.[doi:10.3877//cma.j.issn.2095-9605.2015.03.007]
[9]秦晓光 白日星 宋茂民 闫文貌 汪鑫.胃收缩力调节器治疗2型糖尿病的研究进展[J].中华肥胖与代谢病电子杂志,2015,1(03):157.[doi:10.3877//cma.j.issn.2095-9605.2015.03.011]
[10]殷骏 毛忠琦 徐露 朱政 陈昕 周晓俊 钱海鑫.袖状胃切除联合十二指肠-空肠转流术在非肥胖型2型糖尿病中的应用价值[J].中华肥胖与代谢病电子杂志,2015,1(01):16.[doi:10.3877/cma.j.issn.2095-9605.2015.01.005]
 Yin Jun,Mao Zhongqi,Xu Lu,et al.Application value of the clinical curative effect for laparoscopic sleeve gastrectomy with duodeno-jejunal bypass to treat non-obese type 2 diabetes[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2015,1(03):16.[doi:10.3877/cma.j.issn.2095-9605.2015.01.005]
[11]李延兵.双管齐下:肥胖型2型糖尿病的内科治疗进展[J].中华肥胖与代谢病电子杂志,2015,1(03):113.[doi:10.3877//cma.j.issn.2095-9605.2015.03.001]
[12]张涛涛 张向文 梁怀祝 赵国华.腹腔镜Roux-en-Y胃旁路术治疗肥胖型2型糖尿病的三年随访研究[J].中华肥胖与代谢病电子杂志,2015,1(03):128.[doi:10.3877//cma.j.issn.2095-9605.2015.03.004]
 Zhang Taotao,Zhang Xiangwen,Liang Huaizhu,et al.Three-year follow-up study of laparoscopic Roux-en-Y gastric bypass for treating obese type 2 diabetes mellitus[J].Chinese Journal of Obesity and Metabolic Disease (Electronic Edition),2015,1(03):128.[doi:10.3877//cma.j.issn.2095-9605.2015.03.004]
[13]杨建军 王兵 顾岩.重视肥胖与代谢病外科的卫生经济学管理[J].中华肥胖与代谢病电子杂志,2015,1(03):150.[doi:10.3877//cma.j.issn.2095-9605.2015.03.009]
[14]黄鑫 刘少壮 张光永 胡三元.肥胖症与2型糖尿病的基础研究进展——基于减重手术的探讨[J].中华肥胖与代谢病电子杂志,2016,2(02):61.[doi:10.3877//cma.j.issn.2095-9605.2016.02.001]
[15]李子建 李海龙 陈伟.代谢手术的营养相关问题[J].中华肥胖与代谢病电子杂志,2016,2(02):76.[doi:10.3877//cma.j.issn.2095-9605.2016.02.004]

备注/Memo

备注/Memo:
作者简介:袁振芳,主任医师、硕士研究生导师,北京大学医学部内分泌临床医学博士、日本德岛大学药理学博士。现任北京大学第一医院减重中心内分泌科主任医师,兼任中华医学会内分泌学分会肥胖学组委员、胰岛素抵抗学组委员和北京医学会鉴定专家。担任《中华肥胖与代谢病电子杂志》编委及多种临床杂志的审稿和撰稿专家。自2002年创立北京大学第一医院减肥门诊至今,已积累了丰富的肥胖症诊断和治疗经验。在国内外权威杂志发表了多篇有关肥胖症、糖尿病和甲状腺等疾病的学术论文。
通讯作者:袁振芳,Email:zhenfang_yuan@sina.cn
更新日期/Last Update: 2016-08-30